ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
The exchange is hereby informed that the Company will hold Post Results Conference Call on 29th July, 2019 as per the enclosed details. We request you to kindly take the same on record. Alembic Pharmaceuticals Ltd - 533573 - Board Meeting Intimation for To Consider Unaudited Financial Results For The Quarter Ended 30Th June, 2019
ALEMBIC PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/07/2019 ,inter alia, to consider and approve With reference to the captioned matter, the exchange is hereby informed that a Meeting of Board of Directors of the Company will be held on Monday, 29th July, 2019, inter alia to consider and approve Unaudited Financial Results of the Company for the quarter ended 30th June, 2019. Pursuant to the Company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Designated Persons and their Immediate Relatives, the trading window for dealing in securities of the Company which was closed from 1st July, 2019, will re-open 48 hours after the declaration of the financial results on 29th July, 2019. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
With reference to the captioned matter, please find enclosed herewith a Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th June, 2019, received from M/s. Link Intime India Private Limited, Registrar and Share Transfer Agent of our Company. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Statement Of Investor Complaints For The Quarter Ended June 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0220 Name of the Signatory :- Charandeep Singh SalujaDesignation :- Company Secretary and Compliance Officer ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of Notice of 9th Annual General Meeting, Book Closure and E-voting information published in English and vernacular language (Gujarati) newspaper on 3rd July, 2019 in Economic Times English and Gujarati Edition. We request you to kindly take the same on record. Alembic Pharma gets USFDA nod for Febuxostat tablets
Drug firm Alembic Pharmaceuticals on Tuesday said it has received approval from the US health regulator for Febuxostat tablets, used to lower high le ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
With reference to the captioned subject, this is to inform the exchange that the Company has received US Food & Drug Administration (USFDA) Approval for Febuxostat Tablets, 40 mg and 80 mg. Please find enclosed herewith our press release. We request you to kindly take the same on record. Alembic Pharma gets USFDA nod for seizure treatment drug
Drug firm Alembic Pharmaceuticals on Monday said it has received approval from the US health regulator for Clonazepam orally disintegrating tablets, Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
With reference to the captioned subject, this is to inform the exchange that the Company has received US Food & Drug Administration (USFDA) Approval for Clonazepam Orally Disintegrating Tablets USP, 0.125 mg, 0.25 mg, 0.5 mg, 1 mg and 2 mg. Please find enclosed herewith our press release. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Alembic Clears Its First US FDA Inspection At Solid Oral Oncology Facility At Panelav Mbic Clears Its First US FDA Inspection At Solid Oral Oncology Facility At Panelav
We would like to inform that the United States Food and Drug Administration (US FDA) has conducted an inspection at Company's Solid Oral Oncology facility located at Panelav from 24th June, 2019 to 28th June, 2019. This was a first scheduled inspection and Company passed the inspection without any Form 483 Observation. We request you to kindly take the same on record.